NCT00270205View on ClinicalTrials.gov

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
HIV Infections
Interventions
BIOLOGICAL

LC002 standard vaccination

0.1 mg DNA/participant, 0.8 ml total administered subcutaneously

BIOLOGICAL

LC002 high-dose vaccination

0.4 mg DNA/participant, 3.2 ml total administered subcutaneously

BIOLOGICAL

LC002 placebo vaccination

Placebo vaccination administered subcutaneously

Trial Locations (5)

60614

Chicago Children's CRS, Chicago

95814

Univ. of California Davis Med. Ctr., ACTU, Sacramento

44106-5083

Case CRS, Cleveland

44109-1998

MetroHealth CRS, Cleveland

15213-2582

University of Pittsburgh CRS, Pittsburgh

All Listed Sponsors
collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00270205 - Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART | Biotech Hunter | Biotech Hunter